Idarubicin in combination with etoposide and cytarabine in adult untreated acute non lymphoblastic leukemia

Angelo M. Carella, Marina Martinengo, Gino Santini, Eugenia Gaozza, Eugenio Damasio, Domenico Giordano, Sandro Nati, Angela Congiu, Raffaella Cerri, Marco Risso, Fabrizio Ganzina, Alberto M. Marmont

Research output: Contribution to journalArticlepeer-review


Thirty-one unselected patients with untreated acute non lymphoblastic leukemia (ANLL) ranging in age from 15 to 76 years received two courses of a new high-dose induction regiment consisting of idarubicin, etoposide and cytarabine. Patients who entered complete remission (CR) were then allocated to post-remission intensification (PRI). Patients under 40 years of age with a HLA-compatible donor were given bone marrow transplantation (BMT); those without an HLA identical donor received either autologous BMT (ABMT) or no subsequent therapy. Twenty-five out of 31 patients (80.6%) achieved CR (93.3% in young and 68.7% in old patients) and 14 (56%) after the first cycle. Six patients (five out six > 40 years) died of cerebral hemorrhage and/or infection during the induction phase and four additional patients (three elderly) died on the PRI for the same cause without recurrent disease. Eleven out 25 patients are disease-free survivors 2-34 months (median 10 months) after achievement of CR. In conclusion, this intensive chemotherapy regimen is effective both in young and older patients but the post-remission intensification is too aggressive in elderly patients.

Original languageEnglish
Pages (from-to)1673-1678
Number of pages6
JournalEuropean Journal of Cancer and Clinical Oncology
Issue number11
Publication statusPublished - 1987

ASJC Scopus subject areas

  • Oncology


Dive into the research topics of 'Idarubicin in combination with etoposide and cytarabine in adult untreated acute non lymphoblastic leukemia'. Together they form a unique fingerprint.

Cite this